[go: up one dir, main page]

US20080207717A1 - Composition to provide maintenance and nutritional support in glycemic control deficits - Google Patents

Composition to provide maintenance and nutritional support in glycemic control deficits Download PDF

Info

Publication number
US20080207717A1
US20080207717A1 US11/710,893 US71089307A US2008207717A1 US 20080207717 A1 US20080207717 A1 US 20080207717A1 US 71089307 A US71089307 A US 71089307A US 2008207717 A1 US2008207717 A1 US 2008207717A1
Authority
US
United States
Prior art keywords
canceled
composition
milligrams
botanically
dietary supplement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/710,893
Other versions
US7416750B1 (en
Inventor
Angelica Vrablic
Schneider Glenn
Silverman Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natures Bounty Co
Original Assignee
NBTY Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NBTY Inc filed Critical NBTY Inc
Priority to US11/710,893 priority Critical patent/US7416750B1/en
Application granted granted Critical
Publication of US7416750B1 publication Critical patent/US7416750B1/en
Publication of US20080207717A1 publication Critical patent/US20080207717A1/en
Assigned to BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT reassignment BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: NBTY ACQUISITION, LLC, NBTY MANUFACTURING, LLC, NBTY, INC., THE ESTER C COMPANY
Assigned to BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT reassignment BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: NBTY MANUFACTURING, LLC, NBTY, ACQUISITION, LLC, NBTY, INC., THE ESTER C COMPANY
Assigned to THE NATURE'S BOUNTY CO. reassignment THE NATURE'S BOUNTY CO. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NBTY, INC.
Assigned to CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT reassignment CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NBTY ACQUISITION, LLC, NBTY MANUFACTURING, LLC, REXALL SUNDOWN, INC, THE ESTER C COMPANY, THE NATURE'S BOUNTY CO.
Assigned to BANK OF AMERICA, N.A., AS COLLATERAL AGENT reassignment BANK OF AMERICA, N.A., AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NBTY ACQUISITION, LLC, NBTY MANUFACTURING, LLC, REXALL SUNDOWN, INC., THE ESTER C COMPANY, THE NATURE'S BOUNTY CO.
Assigned to CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT reassignment CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NBTY ACQUISITION, LLC, NBTY MANUFACTURING, LLC, REXALL SUNDOWN, INC., THE ESTER C COMPANY, THE NATURE'S BOUNTY CO.
Assigned to NBTY, INC., THE ESTER C COMPANY, NBTY MANUFACTURING, LLC, NBTY ACQUISITION, LLC reassignment NBTY, INC. RELEASE (REEL 038698 / FRAME 0788) Assignors: BANK OF AMERICA, N.A.
Assigned to NBTY, INC., THE ESTER C COMPANY, NBTY MANUFACTURING, LLC, NBTY ACQUISITION, LLC reassignment NBTY, INC. RELEASE (REEL 038697 / FRAME 0846) Assignors: BANK OF AMERICA, N.A.
Assigned to NBTY MANUFACTURING, LLC, NBTY ACQUISITION, LLC, THE ESTER C COMPANY, THE NATURE'S BOUNTY CO., REXALL SUNDOWN, INC. reassignment NBTY MANUFACTURING, LLC RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Assigned to THE ESTER C COMPANY, THE NATURE'S BOUNTY CO., REXALL SUNDOWN, INC., NBTY ACQUISITION, LLC, NBTY MANUFACTURING, LLC reassignment THE ESTER C COMPANY RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Assigned to THE NATURE'S BOUNTY CO., NBTY ACQUISITION, LLC, REXALL SUNDOWN, INC., THE ESTER C COMPANY, NBTY MANUFACTURING, LLC reassignment THE NATURE'S BOUNTY CO. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • Diabetes, metabolic syndrome, impaired glucose tolerance and related problems in glycemic control and management are tremendous public health concerns which affect millions of people in the United States and worldwide.
  • Diabetes is believed to have multiple etiologies including, inter alia, genetics, diet, exercise, sleep, caloric intake, trauma, infection, stress, drug use, and/or autoimmune reactions. Diabetes is generally classified into two general categories, where diabetes mellitus is typically known as type I diabetes due to insulin deficiency. Insulin is responsible for the regulation of a variety of metabolic functions, including the conversion of glucose to glycogen to lower the blood glucose level. Other forms of diabetes that can occur due to reduced insulin effectiveness in conjunction with other primary diseases are generally known as type 11 diabetes. Furthermore, diabetes is a chronic disease having a variety of pathological manifestations, and may be accompanied by disorders of lipid metabolism, circulation and glucose metabolism, among other effects.
  • aging may also cause a progressive loss of glucose tolerance possibly based on decreased insulin sensitivity in hypothalamic receptors and/or decreased response to glucose and insulin in the peripheral tissue. Should a glucose tolerance loss become pronounced, the condition would be diagnosed and treated as diabetes would be.
  • composition that assists in managing glycemic control and levels with nutritional support beneficial for those affected by such deficits.
  • the Composition may be used to provide nutritional support for mammals inflicted with glycemic level concerns and assist in managing glycemic control problems such as, for example, diabetes, metabolic syndrome, impaired glucose tolerance, and related glycemic deficits and problems.
  • This disclosure relates to a dietary supplement Composition for supporting positive health and bodily nutrition, and managing deficits in glycemic levels, or blood glucose (sugar) levels, in mammals.
  • Deficits in glycemic control may include, for example, diabetes, metabolic syndrome, and related disorders or problems associated with glycemic control.
  • This Composition includes a combination of naturally-occurring, botanically-derived ingredients, such as natural compounds and extracts having hypoglycemic properties, and vitamin components, which combine to produce synergistic and complementary beneficial effects in mammals.
  • This Composition may also alleviate the various symptoms associated with glycemic deficits, by supporting and improving the general bodily health of a mammal suffering with such concerns.
  • the Composition is a synergistic combination of nopal, a species of Opuntia, also known as prickly pear cactus; cinnamon or cinnamon extract (Cinnamomum cassia); chlorogenic acid which is typically found in green coffee beans and berries; biotin; and pantothenic acid, each of which separately is known to positively affect glycemic control, and in combination provides additional positive synergistic effects.
  • Nopal particularly the cactus petal portion of the plant, is widely used as a food in the Southeastern United States, Mexico, and other areas. It is also used as a folk remedy for glucose control in those areas.
  • Nopal has high soluble fiber content and a high pectin content, which may slow intestinal glucose uptake and account, at least partially, for its hypoglycemic properties. Studies have found distinct improvements in diabetics after nopal ingestion, and the results suggest increased or enhanced insulin sensitivity. Importantly, no negative side effects have been found with nopal ingestion and use.
  • the nopal petal also provides a rich source of vitamins A and C.
  • Cinnamon and cinnamon extract is obtained from the bark of the Cinnamomum cassia tree, and has long used a medicinal herb and a spice.
  • MHCP methylhydroxy chalcone polymer
  • MHCP is also known as type A procyanidin oligomers of cathechins and epicatechins.
  • Biotin is a water-soluble B vitamin that is found in animals, plants and microorganisms that enhances the secretion of insulin in animals as well has playing an important role in the metabolism of fatty acids, sugars, and alpha-amino acids.
  • Biotin supplementation has been shown to enhance insulin sensitivity and increase the activity of glucokinase, which activates the utilization of glucose by the liver.
  • Biotin supplementation has also been shown to significantly reduce fasting blood glucose levels and improve blood glucose control in insulin dependent diabetes meliltus and non-insulin dependent diabetics in several studies.
  • Chlorogenic acid is a polyphenol found in berries, coffee (particularly green coffee beans), other foods, and their extracts. Studies have shown chlorogenic acid to be an inhibitor of hepatic glucose-6-phosphate translocase, and this enzyme is responsible for the production of endogenous glucose via gluconeogenesis and glycogenolysis, both of which are important in the homeostatic regulation of blood glucose levels. Inhibitors of glucose-6-phosphate translocase may assist in the reduction of the inappropriately high rates of hepatic glucose output, which is commonly found in non-insulin dependant diabetes.
  • Pantothenic acid also known as vitamin B5
  • Pantothenic acid is necessary to form coenzyme-A, and is important in a number of biological reactions, including the production of energy, the catabolism of fatty acids and amino acids, the synthesis of fatty acids, phospholipids, sphingolipids, cholesterol and steroid hormones, and the synthesis of heme and the neurotransmitter acetylcholine. It also appears to be involved in the regulation of gene expression and in signal transduction.
  • the novel Composition combines ingredients, all of which are naturally occurring, that synergistically retard intestinal glucose uptake, enhance glucose metabolism, enhance uptake by cells, and reduce inappropriately high hepatic glucose out.
  • the Composition accomplishes these facets of glycemic control and nutritional support without negative side efforts, or negative ingredient interactions.
  • the Composition may also be ingested with little or no interaction with traditional medications and medicaments.
  • the Composition may be formed into an easily ingestible supplement, such as, for example, capsules, tablets, powders, liquid concentrates, ready-made drinks, pastes and the like.
  • the Composition may be formed as a capsule for individual doses.
  • the daily dosages for each ingredient of the Composition fall within the following approximate ranges: 1 g (gram) to 5 g of nopal or nopal extract; 100 mg (milligram) to 1 g of cinnamon or cinnamon extract; 50 mg to 300 mg of chlorogenic acid; 50 ⁇ g (microgram) to 200 ⁇ g of biotin; and 1 mg to 50 mg of pantothenic acid. Each of these ranges is within the approximate daily dosage for a mammal.
  • These ingredients may be combined by any convenient or conventional means to a form useful for ingestion or bodily absorption.
  • a capsule may be formed in any convenient size by any convenient method or conventional process, often formed in a 500 mg size for ease of swallowing.
  • a proper dosage level for a particular individual may include the ingestion of more than one capsule.
  • a 500 mg capsule may include the Composition ingredients for combination in the approximate ranges of: 200 mg to 400 mg of nopal or nopal extract; 25 mg to 75 mg of cinnamon or cinnamon extract; 15 mg to 20 mg of chlorogenic acid; 25 ⁇ g to 75 ⁇ g of biotin; and, 1 mg to 4 mg of pantothenic acid.
  • An individual may choose to ingest one or more capsules, or a plurality, as desired, according to the amount of Composition in each capsule.
  • a capsule may be formed in any larger or smaller size, such as, for example, as a 750 mg size capsule.
  • a capsule in a 750 mg size would include ingredients in the approximate general ranges of: 300 to 500 mg nopal or nopal extract; 50 to 150 mg cinnamon or cinnamon extract; 25 to 50 mg chlorogenic acid; 25 to 75 ⁇ g of biotin; and 1 to 4 mg pantothenic acid.
  • a larger capsule size may be convenient to a typical user since generally one capsule could provide a daily dosage necessary to control glycemic deficits.
  • the Composition may be formed within the approximate, general ranges of ingredients as a powder, a powder in a sachet, a tablet, a liquid concentrate, a ready-made drink, nutritional bars, dermal patches from absorption through the skin, or a paste format.
  • the novel Composition may be advantageously used by humans, and other mammals, as nutritional support to manage diabetes and other glycemic control problems without negative side effects or chemical interactions typically associated with traditional pharmaceuticals or medicines.
  • the positive synergistic affects of the ingredients of the Composition provide greater benefits than single ingredients and/or previously known combinations. Therefore, the Composition may be readily used by those suffering with glycemic control problems and avoid further health issues caused by negative reactions and interactions that can often be debilitating for those having previously compromised general health.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A Composition to provide nutritional support for mammals having glycemic control and deficit concerns, and assist in managing glycemic controls deficits, with a synergistic combination of natural ingredients.

Description

    FIELD OF THE INVENTION
  • A composition useful for managing and providing nutritional support for glycemic balance and control deficits in animals, and particularly, in mammals, including humans.
    • BACKGROUND
  • Diabetes, metabolic syndrome, impaired glucose tolerance and related problems in glycemic control and management are tremendous public health concerns which affect millions of people in the United States and worldwide.
  • Diabetes is believed to have multiple etiologies including, inter alia, genetics, diet, exercise, sleep, caloric intake, trauma, infection, stress, drug use, and/or autoimmune reactions. Diabetes is generally classified into two general categories, where diabetes mellitus is typically known as type I diabetes due to insulin deficiency. Insulin is responsible for the regulation of a variety of metabolic functions, including the conversion of glucose to glycogen to lower the blood glucose level. Other forms of diabetes that can occur due to reduced insulin effectiveness in conjunction with other primary diseases are generally known as type 11 diabetes. Furthermore, diabetes is a chronic disease having a variety of pathological manifestations, and may be accompanied by disorders of lipid metabolism, circulation and glucose metabolism, among other effects.
  • In addition, aging may also cause a progressive loss of glucose tolerance possibly based on decreased insulin sensitivity in hypothalamic receptors and/or decreased response to glucose and insulin in the peripheral tissue. Should a glucose tolerance loss become pronounced, the condition would be diagnosed and treated as diabetes would be.
  • It would be highly advantageous to provide a composition that assists in managing glycemic control and levels with nutritional support beneficial for those affected by such deficits.
    • SUMMARY
  • A Composition of botanically-derived ingredients, naturally-occurring ingredients, including nopal, cinnamon, chlorogenic acid, biotin, and pantothenic acid, and extracts thereof, which may be formed into a dietary supplement product. The Composition may be used to provide nutritional support for mammals inflicted with glycemic level concerns and assist in managing glycemic control problems such as, for example, diabetes, metabolic syndrome, impaired glucose tolerance, and related glycemic deficits and problems.
    • DETAILED DESCRIPTION
  • This disclosure relates to a dietary supplement Composition for supporting positive health and bodily nutrition, and managing deficits in glycemic levels, or blood glucose (sugar) levels, in mammals. Deficits in glycemic control may include, for example, diabetes, metabolic syndrome, and related disorders or problems associated with glycemic control. This Composition includes a combination of naturally-occurring, botanically-derived ingredients, such as natural compounds and extracts having hypoglycemic properties, and vitamin components, which combine to produce synergistic and complementary beneficial effects in mammals. This Composition may also alleviate the various symptoms associated with glycemic deficits, by supporting and improving the general bodily health of a mammal suffering with such concerns.
  • The Composition is a synergistic combination of nopal, a species of Opuntia, also known as prickly pear cactus; cinnamon or cinnamon extract (Cinnamomum cassia); chlorogenic acid which is typically found in green coffee beans and berries; biotin; and pantothenic acid, each of which separately is known to positively affect glycemic control, and in combination provides additional positive synergistic effects.
  • Nopal, particularly the cactus petal portion of the plant, is widely used as a food in the Southwestern United States, Mexico, and other areas. It is also used as a folk remedy for glucose control in those areas. Nopal has high soluble fiber content and a high pectin content, which may slow intestinal glucose uptake and account, at least partially, for its hypoglycemic properties. Studies have found distinct improvements in diabetics after nopal ingestion, and the results suggest increased or enhanced insulin sensitivity. Importantly, no negative side effects have been found with nopal ingestion and use. The nopal petal also provides a rich source of vitamins A and C.
  • Cinnamon and cinnamon extract is obtained from the bark of the Cinnamomum cassia tree, and has long used a medicinal herb and a spice. Studies done by the U.S. Agricultural Research Services labs, and other labs, suggest that the cinnamon bark constituent, methylhydroxy chalcone polymer (“MHCP”) may be effective in improving the responsiveness of peripheral tissues to insulin and positively supporting sugar metabolism overall within the body. MHCP is also known as type A procyanidin oligomers of cathechins and epicatechins.
  • Biotin is a water-soluble B vitamin that is found in animals, plants and microorganisms that enhances the secretion of insulin in animals as well has playing an important role in the metabolism of fatty acids, sugars, and alpha-amino acids. Biotin supplementation has been shown to enhance insulin sensitivity and increase the activity of glucokinase, which activates the utilization of glucose by the liver. Biotin supplementation has also been shown to significantly reduce fasting blood glucose levels and improve blood glucose control in insulin dependent diabetes meliltus and non-insulin dependent diabetics in several studies.
  • Chlorogenic acid is a polyphenol found in berries, coffee (particularly green coffee beans), other foods, and their extracts. Studies have shown chlorogenic acid to be an inhibitor of hepatic glucose-6-phosphate translocase, and this enzyme is responsible for the production of endogenous glucose via gluconeogenesis and glycogenolysis, both of which are important in the homeostatic regulation of blood glucose levels. Inhibitors of glucose-6-phosphate translocase may assist in the reduction of the inappropriately high rates of hepatic glucose output, which is commonly found in non-insulin dependant diabetes.
  • Pantothenic acid, also known as vitamin B5, is a water-soluble vitamin that is essential to mammalian nutrition. Pantothenic acid is necessary to form coenzyme-A, and is important in a number of biological reactions, including the production of energy, the catabolism of fatty acids and amino acids, the synthesis of fatty acids, phospholipids, sphingolipids, cholesterol and steroid hormones, and the synthesis of heme and the neurotransmitter acetylcholine. It also appears to be involved in the regulation of gene expression and in signal transduction.
  • The novel Composition combines ingredients, all of which are naturally occurring, that synergistically retard intestinal glucose uptake, enhance glucose metabolism, enhance uptake by cells, and reduce inappropriately high hepatic glucose out. The Composition accomplishes these facets of glycemic control and nutritional support without negative side efforts, or negative ingredient interactions. The Composition may also be ingested with little or no interaction with traditional medications and medicaments.
  • The Composition may be formed into an easily ingestible supplement, such as, for example, capsules, tablets, powders, liquid concentrates, ready-made drinks, pastes and the like. In one embodiment, the Composition may be formed as a capsule for individual doses. The daily dosages for each ingredient of the Composition fall within the following approximate ranges: 1 g (gram) to 5 g of nopal or nopal extract; 100 mg (milligram) to 1 g of cinnamon or cinnamon extract; 50 mg to 300 mg of chlorogenic acid; 50 μg (microgram) to 200 μg of biotin; and 1 mg to 50 mg of pantothenic acid. Each of these ranges is within the approximate daily dosage for a mammal. These ingredients may be combined by any convenient or conventional means to a form useful for ingestion or bodily absorption. A capsule may be formed in any convenient size by any convenient method or conventional process, often formed in a 500 mg size for ease of swallowing.
  • Where a capsule is formed into a 500 mg size, a proper dosage level for a particular individual may include the ingestion of more than one capsule. A 500 mg capsule may include the Composition ingredients for combination in the approximate ranges of: 200 mg to 400 mg of nopal or nopal extract; 25 mg to 75 mg of cinnamon or cinnamon extract; 15 mg to 20 mg of chlorogenic acid; 25 μg to 75 μg of biotin; and, 1 mg to 4 mg of pantothenic acid. An individual may choose to ingest one or more capsules, or a plurality, as desired, according to the amount of Composition in each capsule.
  • In another embodiment, a capsule may be formed in any larger or smaller size, such as, for example, as a 750 mg size capsule. A capsule in a 750 mg size would include ingredients in the approximate general ranges of: 300 to 500 mg nopal or nopal extract; 50 to 150 mg cinnamon or cinnamon extract; 25 to 50 mg chlorogenic acid; 25 to 75 μg of biotin; and 1 to 4 mg pantothenic acid. A larger capsule size may be convenient to a typical user since generally one capsule could provide a daily dosage necessary to control glycemic deficits.
  • In alternative embodiments, the Composition may be formed within the approximate, general ranges of ingredients as a powder, a powder in a sachet, a tablet, a liquid concentrate, a ready-made drink, nutritional bars, dermal patches from absorption through the skin, or a paste format.
  • It will be appreciated that the novel Composition may be advantageously used by humans, and other mammals, as nutritional support to manage diabetes and other glycemic control problems without negative side effects or chemical interactions typically associated with traditional pharmaceuticals or medicines. In addition, the positive synergistic affects of the ingredients of the Composition provide greater benefits than single ingredients and/or previously known combinations. Therefore, the Composition may be readily used by those suffering with glycemic control problems and avoid further health issues caused by negative reactions and interactions that can often be debilitating for those having previously compromised general health.
  • It should be understood that the description and examples are only illustrative of the disclosure. Various alternatives and modifications can be devised by those skilled in the art without departing from the disclosure. Accordingly, the present disclosure is intended to embrace all such alternatives, modifications and variances which fall within the scope of the appended claims.

Claims (54)

1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. A dietary supplement Composition of botanically-derived ingredients, consisting of: nopal, cinnamon, chlorogenic acid, biotin, and pantothenic acid.
16. (canceled)
17. The dietary supplement Composition of botanically-derived ingredients of claim 16, wherein the dietary supplement Composition is formed into a capsule.
18. The dietary supplement Composition of botanically-derived ingredients of claim 17, wherein the amount of nopal in a dosage is in the range of 1 gram to 5 grams 200 mg to 100 mg.
19. The dietary supplement Composition of botanically-derived ingredients of claim 18 wherein the amount of cinnamon in a dosage is in the range of 100 milligrams to 1 gram.
20. The dietary supplement Composition of botanically-derived ingredients of claim 19, wherein the amount of chlorogenic acid in a dosage is in the range of 50 milligrams to 300 milligrams.
21. The dietary supplement Composition of botanically-derived ingredients of claim 20, wherein the amount of biotin in a dosage is in the range of 50 micrograms to 200 micrograms.
22. The dietary supplement Composition of botanically-derived ingredients of claim 21, wherein the amount of pantothenic acid in a dosage is in the range of 1 milligram to 50 milligrams.
23. (canceled)
24. (canceled)
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. (canceled)
38. (canceled)
39. (canceled)
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (canceled)
45. (canceled)
46. (canceled)
47. The dietary supplement Composition of botanically-derived ingredients of claim 18, wherein the amount of nopal in a dosage is in the range of 300 milligrams to 500 milligrams.
48. The dietary supplement Composition of botanically-derived ingredients of claim 18, wherein the amount of nopal in a dosage is in the range of 200 milligrams to 400 milligrams.
49. The dietary supplement Composition of botanically-derived ingredients of claim 19, wherein the amount of cinnamon in a dosage is in the range of 50 milligrams to 150 milligrams.
50. The dietary supplement Composition of botanically-derived ingredients of claim 49, wherein the amount of cinnamon in a dosage is in the range of 25 milligrams to 75 milligrams.
51. The dietary supplement Composition of botanically-derived ingredients of claim 20, wherein the amount of chlorogenic acid in a dosage is in the range of 25 milligrams to 50 milligrams.
52. The dietary supplement Composition of botanically-derived ingredients of claim 51, wherein the amount of chlorogenic acid in a dosage is in the range of 15 milligrams to 20 milligrams.
53. The dietary supplement Composition of botanically-derived ingredients of claim 21, wherein the amount of biotin in a dosage is in the range of 25 micrograms to 75 micrograms.
54. The dietary supplement Composition of botanically-derived ingredients of claim 22, wherein the amount of pantothenic acid in a dosage is in the range of 1 milligram to 4 milligrams.
US11/710,893 2007-02-26 2007-02-26 Composition to provide maintenance and nutritional support in glycemic control deficits Active US7416750B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/710,893 US7416750B1 (en) 2007-02-26 2007-02-26 Composition to provide maintenance and nutritional support in glycemic control deficits

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/710,893 US7416750B1 (en) 2007-02-26 2007-02-26 Composition to provide maintenance and nutritional support in glycemic control deficits

Publications (2)

Publication Number Publication Date
US7416750B1 US7416750B1 (en) 2008-08-26
US20080207717A1 true US20080207717A1 (en) 2008-08-28

Family

ID=39711214

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/710,893 Active US7416750B1 (en) 2007-02-26 2007-02-26 Composition to provide maintenance and nutritional support in glycemic control deficits

Country Status (1)

Country Link
US (1) US7416750B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151108A1 (en) * 2008-12-17 2010-06-17 Mark Gorris Food-based Supplement Delivery System
US20100178413A1 (en) * 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252887A1 (en) * 2007-03-19 2012-10-04 Atm Metabolics Lllp Composition and method for treating diabetes and metabolic disorders

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929066A (en) * 1997-08-08 1999-07-27 Nutrition 21 Chromium/biotin treatment of Type II diabetes
US6203819B1 (en) * 1997-03-07 2001-03-20 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US6485760B2 (en) * 1998-12-09 2002-11-26 Futoshi Matsuyama Method for inhibiting increase of blood sugar level or lowering blood sugar level with a lagerstroemia extract
US6551627B1 (en) * 2001-05-03 2003-04-22 Holomed Pharmaceuticals, Ltd. Medicinal herbal compounds for the prevention and treatment of diabetes
US6784206B2 (en) * 2000-04-05 2004-08-31 Ronald G. Udell Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US6787163B2 (en) * 2003-01-21 2004-09-07 Dennis H. Harris Therapeutic treatment for blood sugar regulation
US20040224035A1 (en) * 2003-04-11 2004-11-11 Peter Miller Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport
US20050255215A1 (en) * 2004-05-17 2005-11-17 Agarwala Om P Compositions containing a nopal cactus isolate and method for making same
US7033623B2 (en) * 2002-11-26 2006-04-25 Kao Corporation Mineral absorption enhancer
US7125571B2 (en) * 2003-11-25 2006-10-24 D & E Pharmaceuticals, Inc. Herbal formulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4205870B2 (en) * 2001-04-13 2009-01-07 花王株式会社 Lifestyle-related disease prevention / amelioration agent

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203819B1 (en) * 1997-03-07 2001-03-20 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US5929066A (en) * 1997-08-08 1999-07-27 Nutrition 21 Chromium/biotin treatment of Type II diabetes
US6485760B2 (en) * 1998-12-09 2002-11-26 Futoshi Matsuyama Method for inhibiting increase of blood sugar level or lowering blood sugar level with a lagerstroemia extract
US6716459B2 (en) * 1998-12-09 2004-04-06 Futoshi Matsuyama Composition for inhibiting increase of blood sugar level or lowering blood sugar level
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US6784206B2 (en) * 2000-04-05 2004-08-31 Ronald G. Udell Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US6551627B1 (en) * 2001-05-03 2003-04-22 Holomed Pharmaceuticals, Ltd. Medicinal herbal compounds for the prevention and treatment of diabetes
US7033623B2 (en) * 2002-11-26 2006-04-25 Kao Corporation Mineral absorption enhancer
US6787163B2 (en) * 2003-01-21 2004-09-07 Dennis H. Harris Therapeutic treatment for blood sugar regulation
US20040224035A1 (en) * 2003-04-11 2004-11-11 Peter Miller Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport
US7125571B2 (en) * 2003-11-25 2006-10-24 D & E Pharmaceuticals, Inc. Herbal formulation
US20050255215A1 (en) * 2004-05-17 2005-11-17 Agarwala Om P Compositions containing a nopal cactus isolate and method for making same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151108A1 (en) * 2008-12-17 2010-06-17 Mark Gorris Food-based Supplement Delivery System
US20100178413A1 (en) * 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
US9918489B2 (en) 2008-12-17 2018-03-20 Mark Gorris Food-based supplement delivery system

Also Published As

Publication number Publication date
US7416750B1 (en) 2008-08-26

Similar Documents

Publication Publication Date Title
KR20080105470A (en) Food composition for prevention and improvement of obesity containing ginseng fruit extract
JP5121308B2 (en) Composition for preventing, improving or treating metabolic syndrome
CN103238897A (en) Composite plant solid drink suitable for diabetic patients
EP3705127A2 (en) Composition comprisingsalvia miltiorrhiza
JP2007536250A (en) Nutritional composition for increasing creatine uptake in skeletal muscle
CN109745359A (en) Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof
CN101766274A (en) Antioxidant functional food composition containing bamboo-leaves flavones
KR101415697B1 (en) A pharmaceutical composition comprising the combined extract of Crataegi Fructus and Citri Pericarpium for treating or preventing obesity or lipid-related metabolic disorder
KR101811210B1 (en) Composition for treatment, improvement or prevention of Diabetes comprising extract of fruit of Sorbus commixta as an effective component
US7416750B1 (en) Composition to provide maintenance and nutritional support in glycemic control deficits
KR20210050475A (en) Composition for improving muscle function comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component
US20250205263A1 (en) Oral composition comprising b-escin and the use thereof
KR101691605B1 (en) Pharmaceutical composition and fuctional food composition for prevention or treatment of hyperlipidemia comprising the tsaoko fructus extract
JP2018516987A (en) Pharmaceutical composition or health functional food for prevention and treatment of metabolic disease containing water extract of Aso as active ingredient
KR20100088794A (en) Composition comprising the extract of pleurotus eryngii for treating and preventing diabetic complication and lipid metabolism disorder by type 2 diabetes
KR102112599B1 (en) Anti-obesity composition comprising Punica granatum and Citrus junos extract as effective component
KR101808808B1 (en) Compositions for preventing and treating diabetes or diabetic complications comprising extracts of Acer tegmentosum Maximowoca and Magnolia officinalis Rehd. et Wils.
CA2667829A1 (en) Ingestibles containing beneficial diabetic ingredient
EP3235510A1 (en) Nutritional compositions for the management of glucose metabolism
KR100814949B1 (en) Composition for the prevention and treatment of lipid metabolism disorder and diabetic complication disease containing dandelion extract
CN105106721A (en) Health product with efficacy of reducing blood sugar
KR101695299B1 (en) Composition for preventing or treating obesity or hyperlipidemia containing Piper longum extract, soy extract containing isoflavon and L-carnitin
KR100851586B1 (en) Anti-obesity composition comprising Lactobacillus as an active ingredient
Fahey Health benefits of apple cider vinegar and other common vinegars: A review
KR101664453B1 (en) Fermented Brown Rice Having Hypocholesterolemic and Hypoglycemic Effect, Preparing Method and Use Thereof

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT, NE

Free format text: SECURITY AGREEMENT;ASSIGNORS:NBTY, INC.;NBTY ACQUISITION, LLC;NBTY MANUFACTURING, LLC;AND OTHERS;REEL/FRAME:038697/0846

Effective date: 20160505

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT, NE

Free format text: SECURITY AGREEMENT;ASSIGNORS:NBTY, INC.;NBTY, ACQUISITION, LLC;NBTY MANUFACTURING, LLC;AND OTHERS;REEL/FRAME:038698/0788

Effective date: 20160505

AS Assignment

Owner name: THE NATURE'S BOUNTY CO., NEW YORK

Free format text: CHANGE OF NAME;ASSIGNOR:NBTY, INC.;REEL/FRAME:041867/0145

Effective date: 20161109

AS Assignment

Owner name: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLAT

Free format text: SECURITY INTEREST;ASSIGNORS:NBTY ACQUISITION, LLC;NBTY MANUFACTURING, LLC;REXALL SUNDOWN, INC;AND OTHERS;REEL/FRAME:043698/0122

Effective date: 20170926

Owner name: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLAT

Free format text: SECURITY INTEREST;ASSIGNORS:NBTY ACQUISITION, LLC;NBTY MANUFACTURING, LLC;REXALL SUNDOWN, INC.;AND OTHERS;REEL/FRAME:043704/0560

Effective date: 20170926

Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NEW YO

Free format text: SECURITY INTEREST;ASSIGNORS:NBTY ACQUISITION, LLC;NBTY MANUFACTURING, LLC;REXALL SUNDOWN, INC.;AND OTHERS;REEL/FRAME:043706/0591

Effective date: 20170926

AS Assignment

Owner name: THE ESTER C COMPANY, NEW YORK

Free format text: RELEASE (REEL 038698 / FRAME 0788);ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:044027/0269

Effective date: 20170926

Owner name: NBTY MANUFACTURING, LLC, NEW YORK

Free format text: RELEASE (REEL 038698 / FRAME 0788);ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:044027/0269

Effective date: 20170926

Owner name: NBTY, INC., NEW YORK

Free format text: RELEASE (REEL 038698 / FRAME 0788);ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:044027/0269

Effective date: 20170926

Owner name: NBTY ACQUISITION, LLC, NEW YORK

Free format text: RELEASE (REEL 038698 / FRAME 0788);ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:044027/0269

Effective date: 20170926

Owner name: NBTY MANUFACTURING, LLC, NEW YORK

Free format text: RELEASE (REEL 038697 / FRAME 0846);ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:044027/0444

Effective date: 20170926

Owner name: THE ESTER C COMPANY, NEW YORK

Free format text: RELEASE (REEL 038697 / FRAME 0846);ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:044027/0444

Effective date: 20170926

Owner name: NBTY, INC., NEW YORK

Free format text: RELEASE (REEL 038697 / FRAME 0846);ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:044027/0444

Effective date: 20170926

Owner name: NBTY ACQUISITION, LLC, NEW YORK

Free format text: RELEASE (REEL 038697 / FRAME 0846);ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:044027/0444

Effective date: 20170926

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12

AS Assignment

Owner name: NBTY ACQUISITION, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0410

Effective date: 20210809

Owner name: NBTY MANUFACTURING, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0410

Effective date: 20210809

Owner name: REXALL SUNDOWN, INC., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0410

Effective date: 20210809

Owner name: THE ESTER C COMPANY, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0410

Effective date: 20210809

Owner name: THE NATURE'S BOUNTY CO., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0410

Effective date: 20210809

Owner name: NBTY ACQUISITION, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0544

Effective date: 20210809

Owner name: NBTY MANUFACTURING, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0544

Effective date: 20210809

Owner name: REXALL SUNDOWN, INC., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0544

Effective date: 20210809

Owner name: THE ESTER C COMPANY, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0544

Effective date: 20210809

Owner name: THE NATURE'S BOUNTY CO., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT;REEL/FRAME:057145/0544

Effective date: 20210809

Owner name: NBTY ACQUISITION, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BANK OF AMERICA, N.A., AS COLLATERAL AGENT;REEL/FRAME:057145/0656

Effective date: 20210809

Owner name: NBTY MANUFACTURING, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BANK OF AMERICA, N.A., AS COLLATERAL AGENT;REEL/FRAME:057145/0656

Effective date: 20210809

Owner name: REXALL SUNDOWN, INC., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BANK OF AMERICA, N.A., AS COLLATERAL AGENT;REEL/FRAME:057145/0656

Effective date: 20210809

Owner name: THE ESTER C COMPANY, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BANK OF AMERICA, N.A., AS COLLATERAL AGENT;REEL/FRAME:057145/0656

Effective date: 20210809

Owner name: THE NATURE'S BOUNTY CO., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BANK OF AMERICA, N.A., AS COLLATERAL AGENT;REEL/FRAME:057145/0656

Effective date: 20210809